Kin Meds says more about compounding law on its product pages than almost any seller on this roster, and says nothing at all about what its prices cover. Four other brands here run the same page template.
What Kin Meds charges
Sermorelin: $349 — printed as "Personalized Sermorelin — In stock — Wellness — Cardio + Strength — Sermorelin — Starts At $349". ⛔ No period of any kind is attached: not a month, not a supply length, not a plan term. Its template sibling Elara MD prints the identical figure as "$349/month"
NAD+: $249 — printed as "Personalized NAD+ — In stock — Wellness — Energy +Mood — NAD+ — Starts At $249", with no period attached. The same catalogue carries a nasal spray and a 200 mg troche at higher figures
Kin Meds is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
A figure with no period attached to it
Both product pages print the product name, a stock marker, a wellness category, the compound again, and then the words starts at followed by a number. Nothing follows the number.
There is no month, no supply length, no plan term, no billing cycle. A reader cannot tell whether the figure buys four weeks, a titration cycle or a single vial.
One of the brands running this identical template writes the same numbers with the word month attached. That is the strongest available evidence about what these figures probably mean, and it is evidence about a different company.
This site records both figures as ones that are not monthly rates, because nothing on this seller's own pages says they are.
The disclaimer is unusually good and unusually shared
Each product page carries a compact block of regulatory disclosure: the image is illustrative, the medication is compounded and dispensed by a licensed third-party pharmacy, the seller is not a state-licensed pharmacy nor a drug manufacturer, and compounded medications are not approved.
Four sentences, each of which a reader genuinely needs, printed above the buying section rather than in a terms document. On the disclosure question alone this seller is above the roster median.
It is not this seller's editorial choice. At least one sibling brand running the same template prints the identical block with its own name substituted, which was verified directly rather than assumed.
That matters because an earlier assessment of this family credited the disclaimer to a different brand as its distinguishing feature. It is template furniture, and this review says so.
No operator, and an arbitration provider that looks like one
No sentence naming an operating company was found on the pages read. The legal pages of the sibling brands in this family carry an identical arbitration clause naming a well-known arbitration organisation, and on several of them that organisation's name is the only corporate name on the page.
An automated entity extractor reading those pages returns the arbitration provider and presents it as the operator of several unrelated companies. That failure has been observed on more than a dozen sellers in this market.
This site therefore records no operating company for this seller rather than recording a name-shaped match. An absence is a fact; a wrong name is a lie with a citation.
Screened by brand against the regulator's warning-letter index — the only handle available, since no entity is published — this seller returns a letter.
One letter, one enforcement day, two brands
The letter names this brand and concerns false and misleading claims in a telehealth channel. It is disclosed on the row, linked, and does not move this seller's score or position here.
Its reference number is one digit apart from the letter issued to another seller on this roster, and both carry the same issue date. Two brands, consecutive reference numbers, one enforcement action.
That is a fact about the market rather than about this company, and it is recorded because a reader comparing sellers should know that enforcement in this sector arrives in sweeps rather than one company at a time.
No dispensing pharmacy is named beyond its licensing category, no certificate of analysis exists on the pages read, and no state coverage list is published.
Who it's for
Readers who want a seller to state, on the product page, that it is not a pharmacy or a manufacturer and that compounded medications are not approved.
Buyers comparing routes, since this brand prices an injection, a nasal spray and a troche.
Anyone who wants stock status on the product page.
Shoppers using this brand as the reference point for the four others here running its template.
Who should look elsewhere
Anyone who needs to know what a price covers, which neither figure states.
Readers who want an operating company published anywhere.
Buyers for whom an enforcement letter naming the brand is disqualifying.
Shoppers who want a certificate of analysis, a named pharmacy, or a state coverage list.
Strengths
Prints, on the product page itself, that it is not a state-licensed pharmacy nor a drug manufacturer and that compounded medications are not FDA-approved
Marks stock status on the product page
Publishes more routes than most of its template siblings — an injection, a nasal spray and a troche, each priced
Says in plain words that the medication is compounded and dispensed by a licensed third-party pharmacy
Trade-offs
Neither figure carries a period, so nothing on the page says what the money buys
No operating company is published anywhere on the pages read
Carries an FDA warning letter for false and misleading claims
Four other brands on this roster run the same page template, so its numbers are not an independent observation of the market
FDA disclosure
Kin Meds received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
How we verified this
Loaded both product pages and a legal page with a full browser user-agent, printing the effective URL beside the requested one on each.
Ran a nonsense-path control on the host in the same run, which returned a not-found status.
Joined the page's text nodes before matching any figure, so a price split across elements could not read as an absence.
Read each figure together with the words on either side of it and recorded that nothing followed it, rather than assuming a month.
Verified the shared regulatory disclaimer directly on this brand and on a sibling brand rather than accepting an earlier assessment that credited it to one of them alone.
Compared this brand's figures against the four sibling brands running the same template and recorded that three of the five publish identical numbers.
Declined to record any operating company, because the only corporate names available on this family's legal pages belong to an arbitration provider.
Screened the brand name against the regulator's warning-letter index, with a nonsense query as a control in the same run, and compared the returned reference number against the other letters found in this batch.
A provider to compare Kin Meds against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Nothing on either product page says. The figure is a starts-at with no period, supply length or plan term attached.
Who operates this brand?
No operating company was found on the pages read. The only corporate name available on this family's legal pages is an arbitration provider's, which is not the operator.
Does it have a warning letter?
Yes, over false and misleading claims. It is disclosed here and does not affect the seller's score or position.
Is the disclaimer on the product page unique to this seller?
No. At least one sibling brand running the same page template prints the identical block with its own name substituted.
How many other brands run this template?
Four others on this roster, and their prices are not all the same — which is why each is reviewed separately rather than collapsed into one.
Kin Meds is not a paid partner; this link may earn a commission if that changes. Full disclosure.